Anna Protopapas Mersana Therapeutics CEO Rating

Mersana Therapeutics CEO Anna Protopapas Bio

Ms. Anna Protopapas has been the Chief Executive Officer and President of Mersana Therapeutics, Inc. since March 2015. Ms. Protopapas has extensive strategic leadership experience and a demonstrated track record of results in the biopharmaceutical industry. She served as the President of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda since May 22, 2013 and served as its Chief Executive Officer since May 09, 2013, Senior Vice President of Corporate Development and Strategy since March 14,2005, Member of the Leadership Team since January 2006 and Executive Officer since January 2006. During her tenure at Millennium, she had been a key driver in forging partnerships that have generated significant revenue and value for Millennium Pharmaceuticals Inc., including collaborations with Johnson & Johnson Pharmaceuticals Research and Development L.L.C., Aventis Pharmaceuticals and Abbott Laboratories. She joined Millennium in 1997 with diverse experiences ranging from business development to international marketing and chemical manufacturing. She served as an Executive Vice President of Global Business Development and Corporate Officer at Takeda Pharmaceuticals International, Inc. since June 24, 2011, where she was responsible for global acquisitions, partnering, licensing and venture investing. She served as an Executive Vice President at Takeda Pharmaceutical Company Limited and also served as the Head of Oncology Business from May 2013 to October 01, 2014 and Corporate Officer since June 24, 2011. She has been a Director of Bioverativ Inc. since March 2, 2017 and Mersana Therapeutics, Inc. since March 2015. She served as a Director of Ariad Pharmaceuticals, Inc. from April 28, 2015 to February 16, 2017. She served as a Director of Ensemble Therapeutics Corporation (Formerly Ensemble Discovery Corporation). Ms. Protopapas holds a BS in Chemical Engineering from Princeton University, a MS in Chemical Engineering from Massachusetts Institute of Technology and a Master's in Business Administration from Stanford University.

Mersana Therapeutics CEO Anna Protopapas At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Mersana Therapeutics.

Based on 4 ratings, Anna Protopapas ranks right above Biogen's CEO, Michel Vounatsos.

Overall, the CEO score has remained stable over the last 90 days.